APT is increasingly confident that they have the phages needed to tackle whatever dangerous bugs are circulating in the US and beyond. So confident, in fact, that in late 2022 the company launched a challenge to the infectious disease community: they will pay $1,000 to any researcher who has a strain of bacteria (from the CDC’s six most dangerous bacterial species, the so-called ESKAPE pathogens) that cannot be killed by phages in the APT library.
